UCSF was one of the first trial sites for a novel mRNA cancer vaccine

Key Points:

• Mark Orwig, diagnosed with facial melanoma in 2023, participated in a UCSF clinical trial testing a pioneering mRNA vaccine designed to harness the immune system to fight cancer, developed by Merck and Moderna.
• The vaccine trial, led by oncologist Dr. Adil Daud, involved about 1,000 patients and combined the vaccine with immunotherapy drug Keytruda, showing promising early results of reduced cancer recurrence compared to Keytruda alone.
• This mRNA vaccine technology allows for rapid, personalized vaccine production targeting specific tumor markers, representing a novel approach that could extend to other cancers beyond melanoma.
• While side effects such as headaches and fatigue were significant, they were comparable to immunotherapy alone, and the trial's full data is expected to be released later, with oncologists expressing cautious optimism.
• Advances in melanoma treatment have significantly improved survival rates over the past two decades, with life expectancy now around six years for diagnoses similar to Orwig’s, who is currently three years post-diagnosis with clear scans.